Current therapeutic strategies for Huntington's disease (HD) are focused on symptom management of disease progression. Transcriptional dysregulation is one of the major characteristics in HD. REST is a transcriptional repressor that silences gene expression through binding to RE1/NRSE sites found in the regulatory regions of numerous neuronal genes. Dysregulation of REST and its targeted genes has been reported in different cell and mouse HD models, as well as in biopsies from human patients. In this work, we characterized transcriptional dysregulation associated with REST in two different HD mouse models and assessed the therapeutic effect of interfering with REST function by overexpressing a dominant-negative form (DN:REST). We show that delivery of DN:REST in the motor cortex restores brain-derived neurotrophic factor (BDNF) mRNA and protein levels by reducing endogenous REST occupancy at the Bdnf locus. Similarly, expression of other REST-regulated genes such as Synapsin I (Syn1), Proenkephalin (Penk1) and Cholinergic receptor muscarinic 4 (Chrm4) were restored to normal levels while non-REST-regulated genes were unaffected. This is the first study conducted to investigate REST's role in vivo in a neurodegenerative disease. Our data show that DN:REST in motor cortex reversed RESTs repressive effects on target genes. However, the lack of therapeutic effect on motor function suggests that a more widespread rescue of REST-regulated sites in the affected brain regions may be necessary.
INTRODUCTION
RE1-silencing transcription factor (REST) is a transcriptional repressor that regulates gene expression by binding to a 21-23 bp DNA regulatory motif known as RE1/NRSE. [1] [2] [3] REST is highly expressed in non-neuronal tissues where it silences the expression of target genes. In the brain it is detected at lower levels and participates in regulating expression of neuronal genes essential for differentiation, homeostasis, neuronal communication and neuronal plasticity. [4] [5] [6] [7] [8] [9] Bioinformatic and experimental approaches have identified several thousand REST target genes in the mouse and human genomes, including those encoding key neuronal proteins such as brain-derived neurotrophic factor (Bdnf), Proenkephalin (Penk), Synapsin I (Syn1), and CN2A sodium channel, voltagegated, type II (Scn2a1) 5, [10] [11] [12] and, more recently, the expression of neuronal non-coding RNAs such as mir-124 and mir-9/9*, with the latter reciprocally involved in the regulation of REST and CoREST protein levels. [13] [14] [15] Dysregulation of REST and its target genes have been implicated in cerebral ischemia 16, 17 cancer, [18] [19] [20] [21] [22] Down syndrome, [23] [24] [25] cardiac hypertrophy, [26] [27] [28] epilepsy 4, 29 and in the molecular pathophysiology of Huntington's disease (HD). 7, 8 HD is a fatal neurodegenerative disease caused by the polyglutamine expansion in the N-terminus of the huntingtin protein. 30 Huntingtin regulates REST function in the brain; 31 normal huntingtin retains REST in the cytoplasm in a multi-protein complex, reducing its nuclear availability and repressor function. In HD, mutant huntingtin cannot interact with REST allowing its translocation to the nucleus and repression of target genes. 7, 32, 33 Indeed, REST-regulated genes are enriched among downregulated genes in human HD caudate samples. 14, 33, 34 Similar molecular hallmarks have been found in peripheral cells from HD patients. 35 A relevant REST-regulated gene is the neuronal survival factor BDNF, a neurotrophin produced in cerebral cortex and delivered to the striatum where it promotes neuron activity and survival. 36 BDNF levels are reduced in cerebral cortex from patients and several HD animal models, and may contribute to striatal neuron vulnerability. 36 The levels of several REST-regulated micro-RNAs have also been found to be altered in mouse and human HD samples. [13] [14] [15] 37 Overall, dysregulation of REST in HD affects a number of molecular targets, highlighting REST as a potential therapeutic target. In previous in vitro studies, using mutant huntingtin knock-in cells, we attenuated REST binding to targets by overexpressing a dominant-negative form lacking co-repressor interaction domains (DN:REST). 33 Similarly, in vitro transfection of decoy oligonucleotides for REST in this HD model restored mRNA and protein levels of several neuronal targets. 38 Thus, efforts are underway to identify compounds that can interfere with REST. [39] [40] [41] Whereas in vitro studies show that relief of REST-mediated repression was beneficial, its utility in vivo remains untested.
Here we investigated the effects of overexpressing DN:REST in two different HD mouse models, the BACHD 42 and the N171-82Q mice 43 models. Delivery of adeno-associated viral vectors (AAVs) expressing DN:REST abrogated REST interaction with RE1/NRSE sites in cortical and striatal tissues and rescued BDNF levels. DN:REST also increased expression of other REST target genes, including Chrm4, Penk1 and Syn1.
RESULTS
Gene expression changes of REST-regulated genes in BACHD and N171-82Q mice We first examined transcriptional changes associated with dysregulation of REST in BACHD and N171-82Q mice. BACHD mice express the human full-length huntingtin with 97 CAG repeats, 42 show cortical and striatal atrophy and progressive motor deficits from 2 months. At 6 months, motor deficits are more robust and BDNF levels are reduced by 60-70%. 42 We determined REST occupancy by chromatin immunoprecipitation (ChIP) assay for the REST-regulated genes Bdnf, Chrm4, Penk1 and Syn1 on samples obtained from BACHD and control mice at 2, 4 and 6 months of age. As shown in Figure 1a , REST occupancy was significantly increased at these loci at 6 months of age. For Bdnf, a trend of increased occupancy was present at 2 months and was significant by 4 months. At 6 months, increased REST occupancy at the Bdnf, Chrm4, Penk1 and Syn1 loci was mirrored by reduced mRNA levels (Figure 1b ). For Bdnf, this was associated with a 45% and 20% reduction in protein levels in motor cortex and striatum, respectively (Figure 1c) . Thus, pathological occupancy of REST in BACHD mice occurs at early disease stages but at a variable level depending on the loci. At 6 months, there was uniform increased occupancy and reduced transcription for all genes tested.
N171-82Q mice express the 171 N-terminal amino acids of human huntingtin, contains 82 polyglutamine repeats and is transcribed by the mouse prion protein promoter. 43 At 20 weeks, BDNF protein level in the striatum and cortex was decreased 70-80%. 43 At 4 months of age, expression levels of Bdnf, Chrm4, Penk1 and Syn1 were robustly affected (Supplementary Figure  S1A) . BDNF protein level was reduced by 55% in cortex and striatum of N171-82Q animals with respect to controls, confirming previous work (Supplementary Figure S1B Figure S2A) and reduced BDNF mRNA and protein levels ( Supplementary Figures S2B and C) . Importantly, compared with mock-treated cells, AAV.DN:REST infection attenuated the transcriptional repressor function of REST (Supplementary Figures S2A-C) . In these short-term studies, overexpression of DN:REST did not affect endogenous REST levels, suggesting that BDNF rescue is from competition between DN:REST and endogenous REST binding at the same RE1/NRSE sites (Supplementary Figure S2D) .
We next injected AAV.DN:REST or AAV.eGFP (AAV e green fluorescent protein) bilaterally into the motor cortex into 6-monthold BACHD or 1.5-month-old N171-82Q transgenic mice (Supplementary Figure S3) . Wild-type age-matched littermates were injected with AAV.eGFP virus as controls. Quantity of neurons transduced have not been evaluated but the transduction of virus into the motor cortex was confirmed using specific antimyc antibodies on western blots to detect the myc-tagged DN:REST (Figure 2a ). One month after injection, mice were killed and brain samples were collected for further analysis. AAV transduction did not alter the repressive effect of REST on its target genes (Figure 2b ). ChIP analyses on BACHD mice injected with AAV.eGFP showed increased REST occupancy at the RE1/ NRSE sites of Bdnf, Penk1, Chrm4 and Syn1 genes (Figure 2b ). This was mirrored by reduced mRNA levels ( Figure 2c ). ChIP analysis on BACHD mice injected with AAV.DN:REST showed 30% reduced REST binding at Bdnf and Penk1 RE1/NRSE sites, but for Chrm4 and Syn1 loci the levels of occupancy were similar to wild type ( Figure 2b ). Gene expression analysis reflected the ChIP data ( Figure 2c ). Quantitative PCR performed on RNA from GFP-positive cortices from AAV.DN:REST-injected BACHD mice showed a 45% increase in BDNF mRNA levels relative to controls (Figure 2c ). BDNF protein levels in cortex and striatum samples of AAV.DN:R-EST-treated, BACHD-treated mice were increased by 20% relative to AAV.eGFP-treated BACHD mice (Figure 2d ). Because BDNF protein is not normally produced in striatum, the data suggest that restoration of BDNF in cortex may be subsequently delivered to striatum.
Similar results were obtained with the N171-82Q mice. Two month after AAV injection, mice were killed and samples analyzed for REST repressor function on target genes. All tested RESTregulated genes were reduced in AAV.eGFP-treated N171-82Q mice compared with AAV.eGFP-treated wild-type mice (Figure 3a ).
The mRNA levels of Bdnf, Chrm4, Chrnb2, Penk1, Snap25 and Syn1 were completely rescued in AAV.DN:REST-treated N171-82Q mice ( Figure 3a) . Importantly, BDNF protein levels were restored in cortex and to B60% in striatum ( Figure 3b ).
The mouse Bdnf gene is complex with eight 5 0 untranslated exons (I-VIII) and one protein coding exon (IX), with transcription from separate promoters. 44 Reduced Bdnf gene transcription in HD models is attributed, in part, to increased REST occupancy of the RE1/NRSE silencer within Bdnf promoter II. To test whether DN:REST reduced promoter II transcription, we analyzed transcripts before and after DN:REST delivery to control, BACHD or N171-82Q mice cortices. As shown in Figure 4a , Bdnf mRNA II is reduced in BACHD mice. At 6 months, Bdnf mRNA I, IV and VI was decreased (Figure 4a ), probably due to mutant huntingtin. Figures S4A and  B) . Likewise, transcripts that are reduced in HD but do not contain REST regulatory sites, such as HmgCR and 7-Dhcr 45 or Lamp1 and Tpp1, 46 were not altered in either BACHD or N171-82Q mice (Supplementary Figures S5A and B) .
Together the data show that DN:REST in motor cortex reversed REST repressive effects on target genes and rescues BDNF protein levels in cortex and striatum in two HD mouse models. 1 week before treatment, with no differences between groups detected (Figures 5a and b) . This is in line with previous findings showing that motor deficits in BACHD mice starts at 2 months of age and increases progressively over time. 42 At 4.5 months from injection, both BACHD groups had significant Rotarod deficits and decreased latency to fall compared with the control wild-type littermates.
Given the lack of therapeutic effect, we tested whether DN:REST continued to rescue transcription of BDNF and other neuronal genes. We found DN:REST protein levels to be persistent at the 4.5-month time point (Figure 5c ). Also AAV.DN:REST-treated BACHD mice had 50% increased Bdnf mRNA levels relative to AAV.eGFP-treated ones (Figure 5d ). A significant increase was also observed in Chrm4 mRNA levels (Figure 5d ). Curiously and in contrast to our in vitro work (Supplementary Figure S2) , BACHD mice treated with DN:REST 4.5 months earlier showed a 3.5-fold increase in endogenous REST mRNA expression relative to AAV.eGFP-treated BACHD mice (Supplementary Figure S6) . Lack of a therapeutic effect on motor function may reflect incomplete rescue of genes involved in motor rescue that show, indeed, a higher occupancy (and lower) expression at 6 months.
DISCUSSION
REST is a transcriptional repressor that regulates expression of genes crucial for proper brain development, neurogenesis and neuronal differentiation. [1] [2] [3] More importantly, many studies have highlighted that abnormalities in REST activity may participate in several cancers and brain diseases. 31, 47 Among the latter, the best example is given by HD in which REST ability to bind to target sites on genomic DNA has been linked to huntingtin protein and to the genetic defect responsible for the disease. Increased REST occupancy at RE1/NRSE sites and reduced transcription from the same loci is a molecular disease phenotype described in several HD cellular and mice models as well as in the human brain and peripheral tissues. 7, 31, 33, 35, 36 In this paper, REST ChIP analyses on cortical samples from BACHD and N171-82Q mice further demonstrate increased REST occupancy in HD that occurs early in the disease process.
We focused on the use of DN:REST and on the advantage of AAV viral vectors to support efficient and region-specific delivery of DN:REST by direct injection into the motor cortex. We delivered DN:REST in this brain region with the aim to increase BDNF protein in cortex and striatum and to re-establish the transcription of other RE1-controlled genes that are down-regulated in HD. We show that in vivo overexpression of DN:REST in the motor cortex of symptomatic BACHD and N171-82Q mice (showing a 'REST phenotype') reduces REST occupancy and increases the expression of different REST target genes. We also show that BDNF mRNA and protein are restored in cortex and striatum of BACHD and N171-82Q mice treated with DN:REST due to attenuation of REST binding at the Bdnf locus. In particular, BDNF levels increase as a result of increased activity of BDNF promoter exon II, which is a direct target of REST. In this study, we also show that DN:REST restores expression driven from BDNF promoter I. These data support previous studies reporting a RE1/NRSE-like sequence in BDNF promoter I that may be activated in the brain and in other tissues, such as the thymus and lung. 48 We also found that long-term expression of DN:REST increased endogenous REST expression. This finding is suggestive of a scenario whereby sustained expression of DN:REST competes for REST-bindings sites, including those upstream of the Rest gene, 13 resulting in upregulation of endogenous REST levels. This could contribute to the absence of motor improvement as measured by the Rotarod test. Alternatively, DN:REST could reduce the expression of REST-regulated micro-RNAs that target the REST gene (as, for example, mir-9), thus resulting in the upregulation of endogenous REST mRNA level. Genome-wide analysis and epigenome studies are needed to further elucidate these points. One possible solution may result from DN:REST delivery combined with RNA interference approaches to block the increased expression of endogenous REST protein observed after longterm treatment. It is likely that targeting the striatum as well will be required.
At present, there is no therapy available for the treatment of HD patients. Gene therapy approaches based on AAV vectors are promising in mice and showing efficacy in humans. [49] [50] [51] [52] [53] In the central nervous system, toxicity or inflammatory responses to AAVs are limited, and moreover, expression does not wane over many years in preclinical studies in dogs and non-human primates. 54 In conclusion, this work evaluates in vivo the therapeutic potential of blocking REST activity and demonstrates that the early intracerebral treatment with AAV.DN:REST can delay the 'REST pathological occupancy phenotype' in HD mice, highlighting REST as a relevant target for further development.
MATERIALS AND METHODS

Expression vectors and AAV
The cDNA sequence of DN:REST was amplified by PCR using Expand HiFi Taq polymerase (Roche, Mannheim, Germany), cloned into pCR2.1-TOPO vector, sequenced and moved into an AAV shuttle plasmids containing the CAG promoter followed by a multi-cloning site upstream of a SV40 polyA sequence. These transcriptional units were flanked at each end by AAV serotype 2 145-bp inverted terminal repeat sequences. The transpackaging plasmids, pBSHSPR2C1, were constructed as follows: genomic DNA was extracted from AAV1 (American Type Culture Collection), and the cap coding sequence was amplified by PCR using Pfx polymerase (Invitrogen, Carlsbad, CA, USA). The AAV2 cap gene was excised from the AAV2 helper plasmid pBSHSPRC2.3 and replaced with the amplified AAV1 cap sequence by using a Swa I restriction site in the rep/cap intergenic junction and a BsrG I site engineered just upstream of the AAV2 poly(A) signal. The resulting trans-packaging construct, pBSHSPR2C1, contains the AAV2 rep gene under the control of a minimal eukaryotic promoter and the AAV1 cap ORF positioned between the AAV2 rep/cap intergenic junction and the AAV2 poly(A) signal. The plasmid pAd-Helper 4.1 (Stratagene; Aligent Technologies, Santa Clara, CA, USA) expresses the E2a, E4-orf6 and viralassociated genes of adenovirus type 5 (Ad5) for AAV amplification. Recombinant AAV vectors were produced by a standard calcium phosphate transfection method in HEK293 cells by using the Ad helper, transpackaging and AAV shuttle plasmids as described. 55 Vector titers were determined by real-time PCR (vector genomes) and transduction units was assessed by fluorescence-activated cell sorter using the HT1080 cell line. The final titers obtained for the AAV vectors used in this study were: AAV2/1.DN:REST (3.12 Á 10 13 genome copies ml
) and AAV2/1.eGFP (3.13 Á 10 13 genome copies ml ). 56 
Mouse models
All animal protocols were approved by the University of Iowa Animal Care and Use Committee. Wild-type FBV and BACHD or wild-type B6C3F1/J and HD-N171-82Q mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Mice were genotyped using primers specific for the mutant human huntingtin transgene flanking the CAG repeat, and transgenic and age-matched wild-type littermates were used for the indicated experiments. In the therapeutic trial, the treatment groups comprised approximately equal numbers of male and female mice. Mice were housed in a controlled temperature environment on a 12-h light/dark cycle. Food and water were provided ad libitum. At the indicated times, mice were injected with either AAV2/1-CAG-eGFP alone or with AAV2/1-CAG-DN:REST plus AAV2/1-CAGeGFP, at a 10:1 ratio, to monitor the efficiency of the injection. For AAV injections, mice were anesthetized with a ketamine and xylazine mix, and 1.5 ml of AAV were injected bilaterally into motor cortex at a rate of 0.2 ml min À 1 (coordinates: þ 0.86 mm rostral to Bregma, þ 1.3 mm lateral to midline, À 0.8 mm ventral to the skull surface). Mice used for gene expression analyses were anesthetized with a ketamine and xylazine mix and perfused with 18 ml of 0.9% cold saline mixed with 2 ml of RNAlater (Ambion) solution, whereas mice used for protein analysis were perfused with 20 ml of 0.9% cold saline. At the indicated times, mice were killed and the brain was removed, blocked and cut into 1-mm-thick coronal slices. Tissue punches from striatum or motor cortex were taken by using a tissue corer (1.4-mm in diameter; Zivic Instruments, Pittsburgh, PA, USA). All tissue punches were flash frozen in liquid nitrogen and stored at À 80 1C until used.
RNA isolation and reverse transcription
We isolated total RNA from cells and tissues with Trizol Reagent (Invitrogen. Genomic DNA was digested with DNA-free (Applied Biosystems, Foster City, CA, USA) at 37 1C for 5 min. Total RNA (1 mg) was reversetranscribed to single-stranded cDNA using Superscript III RNaseH-reverse transcriptase (Invitrogen) and random primers in a volume of 20 ml, according to the manufacturer's instructions.
Chromatin immunoprecipitation
Cells (20 Â 10 6 ) were harvested with trypsin treatment and washed three times with phosphate-buffered saline (PBS; 1X) and then treated with 1% formaldehyde in PBS by rotation for 8-10 min at 4 1C. Fixation was stopped by addition of glycine to a final concentration of 125 mM. Cells were washed two times with PBS, and pellets were suspended in ChIP lysis buffer (10 mM Tris-HCl, pH 8, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate supplemented with 1 mM phenylmethylsulfonyl fluoride, and protease inhibitors mixture MINI (Roche, Basel, Switzerland)) and passed through 25-21 ga needles. For ChIP on mouse tissue, motor cortex was used. The tissue was chopped into small pieces in 5 ml PBS and then treated with 1% formaldehyde with rotation for 10 min at 4 1C. Fixation was stopped by addition of glycine to a final concentration of 125 mM. Fixed tissues were washed three times in PBS and homogenized in 2 ml PBS in a Dounce homogenizer and spun at 400 Â g for 10 min at 4 1C. Pellets were resuspended in 250 ml cell lysis buffer plus 1% sodium dodecyl sulfate (SDS; final concentration) and passed through 25-21 ga needles. An additional 2 ml of lysis buffer without SDS was then added to each sample before sonication. Sonication of the cell and tissue extract was performed four times with 15 s pulses with the microprobe at 40-50% output and 70% duty cycle. To minimize foaming of the solution, sonications were performed in glass tubes. Under these conditions, DNA fragments with an average size of 200-700 bp were obtained. Sonicated extracts were centrifuged, and chromatin yield has been evaluated by ultraviolet spectrometry. Equal amounts of chromatin had been precleared with blocked protein G-Sepharose and were incubated by overnight rotation with 1 mg primary antibodies anti-REST (Millipore, Billerica, MA, USA) and preimmune serum as a negative control for the IP. As a positive control, 1 mg of anti-histone H3 and a corresponding amount of rabbit IgG (Millipore) were used to immunoprecipitate the same chromatin. Protein G-Sepharose (GE Healthcare, Little Chalfont, UK) was added and followed by 1 h of incubation with rotation. Beads were spun at 10,000 Â g for 30 s and washed sequentially with increasing concentrations of salts and nonionic detergents: a first wash was done by using a solution composed of 10 mM Tris-HCl, pH 8, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate and a second wash with 10 mM Tris-HCl, pH 8, 1 mM EDTA, 250 mM LiCl, 0.5% NP40, 0.5% sodium deoxycholate. Finally, beads were eluted with 1% SDS in 0.1 M NaHCO3. Bound fractions were de-cross-linked by adding 200 mM NaCl and by incubation at 65 1C for 6-8 h. De-cross-linked samples were treated with RNase and Proteinase K, and DNA was purified by phenolchloroform, precipitated with two volumes of absolute ethanol, washed two times with 70% ethanol, and pellets were resuspended in 50 ml of HPLC water. Quantitative real-time PCR (iCycler Thermal Cycler with Multicolor Real-time PCR Detection System; Bio-Rad, Hercules, CA, USA) using SYBR Green incorporation was used to quantitatively assess REST occupancy. Three independent PCR experiments were performed for each RE1/NRSE containing site. PCR was performed in a total volume of 20 ml containing equal amounts of input and immunoprecipitated DNA, 50 mM KCl, 20 mM Tris-HCl, pH 8.4, 0.2 mM dNTPs, 25 U ml À 1 iTaq DNA polymerase, 3 mM MgCl2, SYBR Green I, 10 nM fluorescein, stabilizers (iQ SYBR Green Supermix; Bio-Rad) and 0.2 mM of forward and reverse primers. Input from chromatin that had been cross-linked and reversed similar to the analyzed samples represents a control for PCR effectiveness.
Primers flanking the NRSE of the following genes were used: mBdnf S, Quantitative PCR for gene expression Three total RNA preparations were used, and two independent reverse transcription reactions were set up for every RNA stock. Real-time PCR analyses were done in triplicate for each of the analyzed genes to obtain replicates for statistical analyses. DN:REST improves transcriptional changes of REST-regulated genes P Conforti et al 
Western blot
Mouse cortex tissues were lysed in RIPA buffer (50 mM Tris-HcL pH 8, 150 mM NaCl, 0,1% SDS, 1% Nonidet P40, 0,5% Sodium deoxycholate) with 1 mM phenylmethylsulphonyl fluoride, 1 mM dithiothreitol and protease inhibitor (Sigma, St Louis, MO, USA). Lysates were cleaved by centrifugation for 30 min at 12,000 Â g at 4 1C. The resulting supernatant was collected. Protein concentration was determined with the BCA assay and 60-80 mg were loaded on a 10% SDS-PAGE (SDS-polyacrylamide gel electrophoresis) gel. Separated proteins were transferred onto a nitrocellulosa membrane, blocked with 5% non-fat dry milk (Bio-Rad) in Tris buffered saline and 0.1% Tween20 and incubated with primary antibodies (Myc-Tag antibody, Cell Signaling (distributed by Euroclone, Milano, Italia), 1:1000; b-catenin, Cell Signaling, 1:1000) at 4 1C. After washing, filters were incubated 1 h at room temperature with secondary antibodies (peroxidase coniugate, Bio-Rad, 1:3000) and then washed three times with Tris buffered saline and 0.1% Tween20. The SuperSignal West Pico Chemiluminescent Substrate was used to visualize immunoreactive bands by exposure to Amersham ECL Hyperfilm (GE Healthcare, distributed by Euroclone).
Behavior analysis
Mice were tested on an accelerating Rotarod apparatus (model 47,600; Ugo Basile, Comerio, Italy) at 1.5 and 6 months of age. At 1.5 months, mice were first habituated on the Rotarod for 5 min. Mice were then tested three trials per day (with at least 30 min of rest between trials) for four consecutive days and retested in this fashion once more at 6 months of age. For each trial, acceleration was from 4 to 40 r.p.m. over 4 min and then speed maintained at 40 r.p.m. Latency to fall (or if mice hung on for two consecutive rotations without running) was recorded for each mouse per trial. The trials were stopped at 300 s, and mice remaining on the Rotarod at that time were scored as 300 s. Data from the three trials for each group on each day are presented as means±s.e.m.
Statistical analysis
For the statistical analysis, several statistical tests have been used on the basis of the number of the groups of animals (wild-type and HD mice) and the type of treatments (AAV2/1.eGFP and AAV2/1.DN:REST). 
